Autophagy-mitophagy induction attenuates cardiovascular inflammation in a murine model of Kawasaki disease vasculitis

Stefanie Marek-Iannucci, …, Magali Noval Rivas, Moshe Arditi

JCI Insight. 2021. https://doi.org/10.1172/jci.insight.151981.

Graphical abstract

Find the latest version:

https://jci.me/151981/pdf
Autophagy-mitophagy induction attenuates cardiovascular inflammation in a murine model of Kawasaki disease vasculitis

Stefanie Marek-Iannucci1, Asli B. Ozdemir2, Debbie Moreira2, Angela C. Gomez2, Malcolm Lane2, Rebecca A. Porritt2, Youngho Lee2, Kenichi Shimada2, Masanori Abe2, Aleksandr Stotland3, David Zemmour4, Sarah Parker3, Elsa Sanchez-Lopez5, Jennifer Van Eyk3, Roberta A. Gottlieb6, Michael C. Fishbein7, Michael Karin5, Timothy R. Crother2, Magali Noval Rivas2* and Moshe Arditi2,8*

1Graduate School of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
2Department of Pediatrics, Division of Infectious Diseases and Immunology, Infectious and Immunologic Diseases Research Center (IIDRC) and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
3Advanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
4Department of Pathology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA
5Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, CA, USA
6Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
7Department of Pathology, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA, USA

* These senior authors contributed equally.

Corresponding author: Moshe Arditi, MD; moshe.arditi@cshs.org, P: 310-423-4471, Address: 8700 Beverly Blvd, Los Angeles, CA 90048

Short title: Impact of autophagy on murine KD vasculitis

Keywords: Kawasaki disease, Autophagy, Mitophagy, NLRP3, IL-1β, vasculitis

Conflict of interest: The authors have declared that no conflict of interest exists
Abstract

Kawasaki disease (KD) is the leading cause of acquired heart disease among children. Murine and human data suggest that the NLRP3-IL-1β pathway is the main driver of KD pathophysiology. NLRP3 can be activated during defective autophagy/mitophagy. We used the *Lactobacillus casei* cell wall extract (LCWE) murine model of KD vasculitis, to examine the role of autophagy/mitophagy on cardiovascular lesion development. LCWE-injected mice had impaired autophagy/mitophagy and increased levels of ROS in cardiovascular lesions, together with increased systemic 8-OHdG release. Enhanced autophagic flux significantly reduced cardiovascular lesions in LCWE-injected mice, whereas autophagy blockade increased inflammation. Vascular smooth muscle cell specific deletion of *Atg16l1* and global *Parkin*−/− significantly increased disease formation, supporting the importance of autophagy/mitophagy in this model. *Ogg1*−/− mice had significantly increased lesions with increased NLRP3 activity, whereas treatment with MitoQ, reduced vascular tissue inflammation, ROS production and systemic 8-OHdG release. Treatment with MN58b or Metformin (increasing AMPK and reducing ROS), resulted in decreased disease formation. Our results demonstrate that impaired autophagy/mitophagy and ROS-dependent damage exacerbate the development of murine KD vasculitis. This pathway can be efficiently targeted to reduce disease severity. These findings enhance our understanding of KD pathogenesis and identify novel therapeutic avenues for KD treatment.
INTRODUCTION

Kawasaki disease (KD) is an acute febrile illness and systemic vasculitis of unknown etiology with lymphatic and mucocutaneous involvement (1). KD affects children under the age of five, with a slight predominance in males (2, 3). If left untreated, KD leads to cardiovascular complications, such as coronary artery aneurysms (CAA) associated with elevated risk for myocardial infarction, sudden cardiac death and early onset heart failure in young adulthood (4). While high dose intravenous immunoglobulin (IVIG) treatment reduces the incidence of CAA, up to 20% of KD patients are unresponsive to IVIG and require adjunctive therapies (5). KD is currently the leading cause of acquired heart disease in children in the United States, with long-term cardiovascular complications that can be lethal (4-7).

The *Lactobacillus casei* wall extract (LCWE) murine model of KD vasculitis closely phenocopies the important histological, functional and immune features of human KD vasculitis (8, 9). Leucine-rich repeat (LRR)-containing protein 3 (NLRP3) and interleukin-1β (IL-1β) play a crucial role in the development of murine LCWE-induced cardiovascular lesions (8, 10, 11). A similar role for NLRP3 and IL-1β is indicated in human KD, as serum levels of IL-1β are increased and IL-1 related gene expression is upregulated in whole blood of KD patients during the acute phase of the disease (12, 13). Moreover, previous studies have shown that IL-1β promoter polymorphisms that lead to increased IL-1β production are associated with IVIG resistance in KD (14, 15).

Autophagy, a lysosomal degradation process, is responsible for the degradation of intracellular debris, such as dysfunctional proteins and organelles (16). The process involves the formation of a double membrane vacuole called autophagosome, which eventually fuses with the lysosome, leading to a hydrolytic degradation of its cargo with potential recycling of material for cellular function and survival (17). As such, autophagy plays an important role in protecting the homeostasis in cardiomyocytes, endothelial cells and smooth muscle cells under both stressed and unstressed conditions (18, 19). Mitophagy is the autophagic removal of damaged
mitochondria (20). Under the circumstances of impaired mitophagy and accumulation of malfunctioning mitochondria, release of reactive oxidative species (ROS) results in increased oxidative DNA damage, predominantly of mitochondrial DNA (mtDNA) (16). Release of mtDNA can lead to the activation of the NLRP3 inflammasome, eventually causing IL-1β maturation and activation (21, 22). In addition, accumulation of damaged mitochondria has cytotoxic effects on the cell, thus, autophagic clearance of dysfunctional mitochondria is critical for cell survival, specially under stressed conditions (23). Due to their high energetic demand, cardiovascular tissues are especially dependent on autophagy, and defective autophagic flux has been associated with various cardiovascular diseases such as heart failure, hypertension, cardiomyopathy and atherosclerosis in small and large animal models (18, 24-26). Targeting this pathway may be an effective therapeutic option. For example, increasing autophagic flux by intermittent fasting can precondition heart tissue to ischemia-reperfusion injury (27).

If and how autophagy and mitophagy are affected during KD, and whether this pathway can be modulated to prevent or decrease disease severity, have not yet been studied. Here, we used the LCWE murine model of KD vasculitis to characterize the contribution of autophagy and mitophagy to the development of murine KD cardiovascular lesions. We find that autophagy and mitophagy are impaired during LCWE-induced murine KD vasculitis and that genetic, non-pharmacologic and pharmacological modulation of autophagic flux decreases the severity of LCWE-induced cardiovascular inflammation by blocking NLRP3 activation and IL-1β secretion.
RESULTS

Autophagic flux is impaired during LCWE-induced KD vasculitis.

To determine if KD involves impaired autophagy, we used the LCWE murine model of KD vasculitis (11, 28, 29). WT mice were injected with either LCWE or PBS, and the severity of vasculitis was determined one week later by histological quantification of heart vessel inflammation and by assessing the development of abdominal aorta aneurysms (AAA) and dilatations, as previously published (11, 28). As expected (11, 28, 29), compared with control PBS mice, LCWE-injected mice showed intense heart vessel inflammation characterized by the development of aortitis, myocarditis and coronary arteritis (Figure 1A). LCWE injection also resulted in the development of AAA and dilatations (Figure 1B). The LCWE-induced KD murine model of vasculitis is dependent of NLRP3 inflammasome activation (11, 28, 29) and, as expected, IL-1β levels were increased in the serum of LCWE-injected mice compared with control PBS-injected mice (Figure 1C). Since autophagy negatively regulates NLRP3 activation (30), we quantified levels of selected autophagy-regulatory proteins in whole lysate of heart tissue from LCWE- and PBS-injected mice by Western blot (WB) one week after LCWE injection (Figure 1D-I). S6 and phospho-S6 were significantly increased in LCWE-injected mice, suggesting increased activity in the mTOR pathway, which suppresses autophagy (31) (Figure 1D, E). Furthermore, ULK-1 and phospho-ULK-1\textsuperscript{S555} were significantly decreased in the LCWE-injected mice hearts, reflecting a decreased activity of the autophagy-inducing AMPK pathway (Figure 1F, G). Indeed, pAMPK\textsuperscript{T172}/AMPK ratio was significantly reduced in LCWE-injected mice compared to control mice (Figure 1F, G). Accordingly, standard autophagy markers p62 and LC3-II/I ratio were also significantly increased in heart tissues from LCWE-injected mice compared to control mice (Figure 1H, I). Additionally, ATG5 was significantly decreased in the whole lysate of heart tissue from LCWE injected mice (Figure 1H, I). These results may indicate accumulation of autophagosomes due to impaired clearance. We next performed an in vivo autophagic flux assay (32, 33). WT mice were injected with either LCWE or PBS, and one week later, mice received...
either a single dose of CQ (40mg/kg i.p.) or PBS (vehicle control). Heart tissues were collected 4 hours later to quantify LC3-II levels by WB. CQ-treated PBS-injected mice exhibited a significantly stronger increase in autophagic flux than LCWE-injected mice, reflected by a stronger accumulation of LC3-II (Figure 1J). Overall, these results indicate that LCWE-induced KD vasculitis and heart tissue inflammation are associated with a significant decrease in autophagic flux.

**Increasing autophagic flux reduces the development of LCWE-induced cardiovascular lesions.**

To determine if impaired autophagy plays a causal role in NLRP3 activation and the development of LCWE-induced cardiovascular lesions, LCWE-injected WT mice were subjected to intermittent fasting, which is known to increase autophagic flux in cardiovascular tissues (27). Mice were fasted for 24h every other day for one week, beginning on the day of LCWE injection. Body weight was monitored daily and was not affected by intermittent fasting (Supplementary Figure 1A). WB analysis of heart tissues whole lysate showed that intermittent fasting significantly increased the conversion of LC3-I to LC3-II in LCWE-injected mice, indicating increased autophagosome formation (Figure 2A, B). Intermittent fasting also significantly decreased the expression of p62 in these heart tissues, suggesting increased clearance of autophagosomes (Figure 2A, B). Additionally, intermittent fasting significantly decreased pS6/S6 ratio and tended to increase pULK1S555/ULK1 ratio in LCWE-injected mice, suggesting activation of the autophagy-inducing AMPK pathway (Supplementary Figure 1B, C). In the in vivo autophagic flux assay, intermittent fasting led to significantly greater LC3-II accumulation following CQ treatment, indicating increased autophagic flux (Figure 2C). We next assessed if induction of autophagic flux by intermittent fasting affected the severity of LCWE-induced KD vasculitis. Remarkably, enhancing autophagy by intermittent fasting of LCWE-injected mice significantly decreased heart tissue and
coronary artery inflammation and the development of AAA (Figure 2D, E). To determine if increased autophagic flux dampened the development of LCWE-induced cardiovascular lesions by decreasing local NLRP3 activation, we quantified Caspase-1 activity by FLICA staining. Intermittent fasting of LCWE-injected mice strongly decreased Caspase-1 activity compared with LCWE-injected mice kept on a normal feeding regimen (Figure 2F). Additionally, serum IL-1β levels were also significantly reduced in fasted mice (Figure 2G).

As a complementary approach to assess the role of autophagy, we blocked autophagy and lysosome degradation in vivo by treating LCWE-injected mice with PBS or CQ (10mg/kg of body weight) i.p. every other day for one week. CQ treatment of LCWE-injected mice resulted in a significant increase of cardiovascular inflammation as well as AAA formation (Figure 2H, I). Taken together, these results indicate that autophagy plays a key role in determining NLRP3 activation in the LCWE model of KD vasculitis.

Specific deletion of Atg16l1 in smooth muscle cells increases the severity of LCWE-induced KD vasculitis.

Since monocytes and macrophages are the main IL-1β producers in cardiovascular lesions during LCWE-induced KD vasculitis (11, 29), we interrogated the role of autophagy in myeloid cells using Lys\textsuperscript{Cre}Atg16l1\textsuperscript{Δ/Δ} mice, which harbor a specific deletion of Atg16l1 in myeloid cells (34) (Figure 3A). However, LCWE-induced KD vasculitis was similar between Lys\textsuperscript{Cre}Atg16l1\textsuperscript{Δ/Δ} and Atg16l1\textsuperscript{fl/fl} littermate controls (Figure 3B, C), indicating that blocking autophagy specifically in myeloid cells did not prevent NLRP3 activation in this model.

Studies on human tissues and murine models indicate that autophagy in vascular smooth muscle cells (VSMCs) is required for tissue homeostasis, and impaired VSMCs autophagy contributes to the development of AAA (35-38). We therefore assessed the expression of selected autophagy-related genes (Atg16l1, Becn1, Ulk1, Atg4b, Atg5, Sqtstm1, Map1lc3b, Prkaa1, Rps6) as well as
mitophagy-related genes (Optn, Map1lc3b, Bnip3l and Sqstm1) in a publicly available single-cell RNA-seq dataset generated from abdominal aortas of PBS and LCWE-injected mice (39) (Supplementary Figure 2). In the abdominal aorta of LCWE-injected mice, VSMCs undergo a phenotypic switch to type II VSMCs which is dependent of IL-1 signaling and results in increased proliferation, higher expression of fibroblast markers and decreased expression of contractile proteins (39). The expression of autophagy-related genes, including Atg16l1, was decreased in VSMCs type II compared to infiltrating immune cells (Supplementary Figure 2). To determine if blocking autophagy in VSMCs promotes the development of LCWE-induced cardiovascular lesions, Atg16l1fl/fl mice were crossed with Tamoxifen inducible Myh11cre/ERT2 positive mice to generate Myh11cre/ERT2Atg16l1Δ/Δ mice (Figure 3D). LCWE injection resulted in more severe development of abdominal aorta dilatations and heart inflammation in Myh11cre/ERT2Atg16l1Δ/Δ mice than in controls (Figure 3E, F). These results indicate that defective autophagy in VSMCs and not myeloid cells, promotes the development and severity of cardiovascular lesions in the LCWE-induced KD murine model.

LCWE-induced KD vasculitis is associated with impaired mitophagy.

Autophagy and mitophagy, which is the autophagic clearance of dysfunctional mitochondria, play an important role in cardiovascular homeostasis, and their dysfunction is connected to several cardiovascular diseases (18, 40, 41). To further evaluate the role of mitophagy during LCWE-induced KD vasculitis, p62 and LC3 were assessed by WB in mitochondrial fractions isolated from the hearts of LCWE or PBS-injected WT mice. The expression of p62 and LC3II/I ratio were significantly increased in mitochondrial fractions of LCWE-treated mice (Figure 4A, B). Furthermore, LCWE-injection resulted in a significant accumulation of Parkin in the mitochondrial fraction, suggesting impaired degradation of damaged mitochondria (Figure 4A, B). The expression of phospho-Ubiquitin Ser65, a specific marker of ubiquitination in the Pink1-Parkin
mitophagy pathway (42), was also significantly increased in the mitochondrial fraction of LCWE-injected mice compared with control (Figure 4A, B). We next performed WB analysis on whole lysate of heart tissues from PBS and LCWE-injected mice to evaluate the mitochondrial content. The oxidative phosphorylation complexes were significantly increased in whole heart tissue lysates from LCWE-injected mice compared with PBS-injected mice (Figure 4C, D). Mitochondrial respirometry on freshly isolated mitochondria from LCWE- and PBS-injected mouse heart tissue showed that LCWE injection resulted in a significant reduction of maximal respiratory capacity after FCCP treatment, which reflects the mitochondrial capacity of adapting to stress (Figure 4E). Overall, these findings indicate defective mitochondrial clearance and accumulation of functionally impaired mitochondria in heart tissues of LCWE-injected mice. Furthermore, mice that are deficient for Parkin (Parkin−/−), an E3 ubiquitin ligase involved in the degradation of damaged mitochondria by autophagy (43), showed significantly increased heart inflammation scores as well as more severe AAA development compared with WT littermate controls (Figure 4F, G).

We next performed a targeted proteomics-based assay quantifying mitochondrial proteins (MitoPlex) in abdominal aorta tissues collected from WT mice injected with either PBS or LCWE and LCWE-injected mice that were intermittently fasted (44). Most of the proteins analyzed by MitoPlex are involved in carbon chain metabolism and related to mitochondrial functions, oxidative phosphorylation and ROS production (44). Interestingly, intermittently fasted LCWE-injected mice showed reduced expression of mitochondrial proteins in the abdominal aorta tissues compared to non-fasted LCWE injected mice, suggesting that fasting-induced increased autophagic flux promotes mitochondrial clearance (Figure 4H). Furthermore, principal component analysis (PCA) revealed that the expression of mitochondrial proteins separated PBS and LCWE-injected into 2 groups and showed that fasted LCWE-injected mice had a similar mitochondrial protein expression signature to PBS-injected mice, reflecting increased mitochondrial turnover and clearance (Figure 4I). All together, these results suggest that cardiovascular lesion development
in the LCWE-induced murine model of KD vasculitis is associated with impaired mitochondrial clearance, and promotion of autophagy through intermittent fasting results in increased mitophagy and reduced lesion formation.

**ROS and oxidative DNA damage activate NLRP3 and influence cardiovascular lesion formation.**

Mitochondria are a major source of ROS, which contribute to the oxidative stress response through a process mediated mainly by Complex I (45). The accumulation of dysfunctional mitochondria and increased expression of oxidative phosphorylation (OXPHOS) complexes in heart tissues of LCWE-injected mice led us to hypothesize that LCWE-injected mice exhibit increased oxidative stress in vascular lesions. Increased ROS leads to oxidative mitochondrial DNA (mtDNA) damage and the release of mtDNA, a known activator of the NLRP3 inflammasome, into the cytosol (21, 22, 46). Additionally, 7,8-dihydro-8-oxo-2′-deoxyguanosine (8-OHdG), an oxidized derivative of deoxyguanosine and the most important byproduct of oxidative DNA damage (47), can be released into the serum and measured as a reporter of ROS-mediated cellular damage. Therefore, we next measured 8-OHdG in the serum of PBS- and LCWE-injected mice (*Figure 5A*). Interestingly, LCWE injected mice showed significantly increased levels of 8-OHdG in the serum compared with PBS-injected mice (*Figure 5A*). Furthermore, dihydroethidium (DHE) staining and quantification of local ROS production in abdominal aortas of PBS and LCWE-injected mice demonstrated a significant increase of ROS production in the LCWE-injected mice (*Figure 5B*).

8-oxoguanine glycosylase (OGG1) is a base-excision-repair gene for mtDNA oxidative damage which removes 8-OHdG. We next assessed the development of LCWE-induced cardiovascular lesions in *Ogg1*−/− and WT littermate controls (22). LCWE-injected *Ogg1*−/− mice developed more intense heart inflammation and severe AAA compared to their littermate controls (*Figure 5C, D*). FLICA staining on frozen heart tissue sections also indicated a significant increase in Caspase-1
activity in LCWE-injected Ogg1<sup>-/-</sup> mice, reflecting increased NLRP3 inflammasome activation (Figure 5E). Furthermore, compared to WT littermates, LCWE-injected Ogg1<sup>-/-</sup> mice exhibited significantly greater ROS production in abdominal aorta tissues (Figure 5F). These findings are consistent with previously published data (22) and indicate that increased ROS production promotes NLRP3 inflammasome activation and the development of cardiovascular lesions in LCWE-injected mice. We next asked whether reduction of mitochondrial ROS with a mitochondria targeted antioxidant (MitoQ) would have beneficial effects on cardiovascular lesion formation in this model. MitoQ treatment resulted in significant reduction of heart vessel inflammation and AAA development in LCWE-injected mice (Figure 5G, H). MitoQ treatment also decreased oxidative stress in the abdominal aorta, as demonstrated by reduced DHE staining (Figure 5I). Furthermore, 8-OHdG was significantly reduced in the serum of LCWE+MitoQ treated mice compared to controls. These results demonstrate that LCWE-induced cardiovascular lesions have increased local ROS production, resulting in systemic increase of 8-OHdG. Furthermore, defective oxidative damage repair machinery exacerbates disease, whereas ROS reduction attenuates cardiovascular lesions.

**Modulation of AMPKα and ROS reduces cardiovascular lesions during LCWE-induced KD vasculitis.**

To assess the potential of pharmacologically activating autophagy/mitophagy through the AMPK pathway during LCWE-induced KD vasculitis, we treated WT mice with MN58b, a choline kinase α inhibitor, known to activate AMPK and to reduce ROS and mtDNA release (48). MN58b treatment was given daily for 9 days beginning 2 days prior LCWE injection. LCWE-injected mice treated with MN58b had significantly reduced heart inflammation and abdominal aorta dilation compared to LCWE-treated mice (Figure 6A-D). To determine if the beneficial effect of MN58b treatment on LCWE-induced KD vasculitis was mediated by decreased NLRP3 inflammasome
activity, we performed FLICA staining on heart tissues, and observed that Caspase-1 activity was significantly reduced in LCWE-injected mice treated with MN58b compared with LCWE-injected mice (Figure 6E, F). Furthermore, ROS accumulation in abdominal aorta tissue was significantly decreased in MN58b treated LCWE-injected mice (Figure 6G, H).

We next determined if Metformin, also known to activate AMPK and inhibit Complex I (49-51), would decrease the incidence and severity of LCWE-induced cardiovascular lesions. WT mice were treated daily with Metformin starting 2 days before LCWE injection until day 9 post-LCWE injection, when the severity of KD vasculitis was assessed. Metformin treatment significantly reduced heart vessel inflammation and abdominal aorta dilatations compared to controls (Figure 7A, B) and this effect was associated with decreased NLRP3 activity, as observed by FLICA staining (Figure 7C) and reduced levels of IL-1β in the serum (Figure 7D). We next assessed the effects of Metformin treatment during LCWE-induced KD vasculitis on the OXPHOS system by quantifying Complex I (CI), CII, CIII, CIV and CV in heart tissue whole lysate by WB (Figure 7E, F). Metformin treatment resulted in a significant reduction of CI and a trend toward increased expression of CIV in heart whole lysate (Figure 7E, F). Furthermore, to assess local ROS production we performed a DHE staining on frozen abdominal aorta tissue sections. Metformin-treated LCWE-injected mice showed significantly reduced ROS formation in the tissue (Figure 7G). In addition, LC3-I to II conversion was significantly increased in heart tissues of Metformin-treated mice, indicating increased autophagosome formation. On the other hand, the expression of p62 tended to be reduced by Metformin treatment, indicating a possible increase in autophagosome clearance (Figure 7H, I). Furthermore, the pAMPK$^{\text{T172}}$/AMPK ratio was significantly increased in the Metformin-treated group, suggesting increased AMPK phosphorylation, a known mechanism of action of Metformin (Figure 7H, I). Expression of MFF was significantly increased in the whole lysate of heart tissues from LCWE injected mice treated with Metformin, as were pMFF$^{\text{S172/S146}}$, DRP1, pDRP1$^{\text{S616}}$ and OPA1 (long and short fragment), indicating increased mitochondrial fission (Figure 7H, I) (52). These results are consistent with
previously published data demonstrating that Metformin promotes autophagy through the AMPK axis (52). Our results strongly suggest that Metformin treatment activates autophagy through the AMPK pathway and reduces ROS (53), resulting in decreased LCWE-induced KD cardiovascular lesions.

**DISCUSSION**

Here, we show that LCWE injection results in increased expression of proteins of the autophagy-inhibiting mTOR pathway, reduced expression of proteins from the autophagy-promoting AMPK pathway, and accumulation of the autophagic markers p62 and LC3 in heart tissue, indicating decreased clearance of autophagosomes and dysfunctional autophagy (31). Intermittent fasting increases autophagy through activation of the AMPK pathway and inhibition of mTOR (27, 54, 55). In LCWE-injected mice, this was associated with decreased severity of LCWE-induced KD vasculitis and significant reductions of both tissue Caspase-1 activity and systemic IL-1β levels. In contrast, Pharmacological blockade of autophagy in LCWE-injected mice by CQ treatment worsened LCWE-induced KD vasculitis. These results are consistent with previous publications indicating that activation of autophagy may counteract or reduce NLRP3 inflammasome activity in the cell (56-58), and support the importance of the autophagy pathway in modulating the development of cardiovascular lesions in this murine model of KD vasculitis.

Myeloid cells are the main producers of IL-1β in LCWE-induced KD cardiovascular lesions (11, 29), however blocking autophagy specifically in myeloid cells by deletion of Atg16l1 did not further increase the severity of LCWE-induced KD cardiovascular lesions. It is possible that IL-1β production by myeloid cells is already maximal after LCWE-injection, and autophagy might not be sufficient to regulate NLRP3 activation, thus blocking autophagy specifically in myeloid cells did not further promote vasculitis severity.
“Crosstalk” between stromal and immune cells is crucial for multiple biological processes, such as coordination and regulation of immune responses to infectious agents as well as tissue repair and homeostasis (59). These interactions are mediated by immune factors, cytokines and chemokines, but may also occur through the release of microRNAs (miRNAs) and exosomes (60).

In KD patients, hyperactivated platelets produce miR-223, and decreased levels of miR223 were observed in KD patients with coronary aneurysms (61). Furthermore, platelet-derived miR-223 promotes VSMCs differentiation into a phenotype associated with decreased KD vascular inflammation (61). In a murine model of Angiotensin-II induced dissecting abdominal aorta aneurysms, VSMCs clonally expand and undergo a phenotypic switch towards phagocytic-like cells, which is characterized by the upregulation of phagocytic, autophagic and endoplasmic reticulum stress markers (38). In this model, blocking autophagy in VSMCs through the deletion of Atg5 resulted in increased severity of abdominal aortic aneurysms development, decreased autophagosome formation and increased VSMCs apoptosis (38). ScRNA seq analysis of the abdominal aorta from PBS and LCWE-injected mice indicates the emergence of phenotype switch in the VSMCs compartment (proliferating type II VSMCs), which is associated with a pathogenic fibroblastic gene signature (39). These VSMCs type II express Atg16l1, although at lower levels than the infiltrating immune cells. Therefore, we investigated the impact of autophagy in these cells and found that blocking autophagy in VSMCs by deleting Atg16l1 led to a significant aggravation of cardiovascular lesions development in LCWE-injected animals. This is consistent with findings of human and mouse data from other groups, and demonstrates that impaired autophagy in VSMCs enhances AAA formation (35-37). However, how impaired autophagy in VSMCs mechanistically leads to increased cardiovascular lesions formation in this model will require further investigations. Impaired mitophagy results in cytosolic release of mtDNA, a known activator of the NLRP3 inflammasome (21, 22, 46). Therefore, defective autophagy in VSMCs may lead to increased “shedding” of mtDNA through vesicles in cardiovascular tissues resulting...
in increased infiltration of inflammatory cells, activation of the NLRP3 inflammasome and IL-1β release.

We observed impaired autophagy and mitochondrial clearance in LCWE-induced KD cardiovascular lesions. Mitochondrial dysfunction has already been reported in the context of cardiovascular diseases, such as atherosclerosis, heart failure and ischemic heart diseases (40, 62). Compared with febrile controls, KD patients show reduced blood mRNA expression of autophagy-related genes, such as LC3B, BECN 1 and ATG16L1, which are subsequently increasing 21 days after IVIG treatment (63). Interestingly, mRNA levels of ATG16L1 remained low in KD patients with coronary artery lesions development (63), highlighting further the therapeutic potential of promoting the autophagy/mitophagy pathway for KD patients developing coronary artery lesions to avoid damaging tissue remodeling. Indeed, it is of interest to note that, statins, such as Atorvastatin, that have pleotropic anti-oxidant and anti-inflammatory effects that help promote endothelial cell homeostasis and block myofibroblast transformation, has been used in KD patients with giant aneurysms (64), and was found to be safe and well-tolerated in children with acute KD and coronary artery aneurysms in a Phase I/IIa trial (65). It is of interest that several studies have shown that statins can also induce autophagy and mitophagy and thus inhibit NLRP3 inflammasome activation and inflammatory cytokines such as IL-1β, which is linked to the pathogenesis of KD (65-67)

Oxidized mtDNA functions as a damage-associated molecular pattern (DAMP), leading to NLRP3 inflammasome activation (22, 56). We observed increased ROS production in the abdominal aorta dilatations of LCWE injected mice, as well as elevated systemic levels of 8-OHdG. In atherosclerosis, increased ROS and impaired OGG1-dependent DNA repair led to the activation of NLRP3 and plaque formation (22). In this model, Ogg1−/− mice exhibit a more severe cardiovascular inflammation than LCWE-injected littermates, which was associated with increased Caspase-1 activity and ROS production. This is of special interest because prior studies
have described the importance of OGG1 and oxidized mtDNA in the activation of NLRP3 (21, 22).

MitOQ, a mitochondria-specific antioxidant known to improve mitophagy in a PINK1-dependent manner (68), significantly attenuated the severity of LCWE-induced KD vasculitis and significantly reduced tissue ROS production and systemic 8-OHdG release, suggesting that targeting mitophagy might be beneficial to treat IL-1β driven vasculitis.

Since impaired autophagic flux and increased local ROS production are associated with the development of LCWE-induced KD cardiovascular lesions, we reasoned that pharmacological modulation of autophagy/mitophagy, and blockade of ROS production might prevent the development of the disease. Treating LCWE-injected mice with MN58b, a choline kinase α inhibitor that simultaneously activates autophagy through the AMPK axis and reduces ROS production (48), decreased development of LCWE-induced cardiovascular lesions as well as Caspase-1 activity and ROS production, which is consistent with reduced NLRP3 inflammasome activity. Metformin also activates AMPK and inhibits the mitochondrial Complex I, which is the main source of ROS production in the cell (45, 49-51). Metformin treatment also resulted in a significant reduction of cardiovascular lesions and tissue Caspase-1 activity, as well as decreased levels of circulating IL-1β, all consistent with a reduction of NLRP3 inflammasome activation. This is consistent with recent findings of Tsuji G et al. were Metformin treatment led to reduction of circulating IL-1β via inhibition of NLRP3 in keratinocytes (69). Similarly, Yang F et al. recently demonstrated a beneficial effect of Metformin in diabetic cardiomyopathy through autophagy dependent NLRP3 inhibition (70).

Mechanistically, Metformin treatment significantly decreased Complex I expression in heart tissues and ROS production in the abdominal aorta during LCWE-induced KD vasculitis. Furthermore, the AMPK pathway and mitochondrial fission, and therefore mitochondrial turnover, were increased in Metformin-treated LCWE-injected mice compared to controls, which is consistent with previously published data (49-52).
Due to the continuous long-term inflammation resulting in chronic endothelial remodeling in KD patients, even years after disease manifestation, there has been an emerging role of treatment with Statins in this patient collective. It is thought that the statins reduce chronic vascular inflammation and therefore might be beneficial in reducing long-term coronary artery remodeling and CAA formation (5, 64, 71). This enhances the relevance of our manuscript, since it has become more and more evident that statins can enhance autophagy via inhibition of the mTOR axis, as observed by Wei YM et al. in coronary arterial myocytes for instance (72).

In summary, we show that in a murine model of KD vasculitis, enhancing autophagy/mitophagy has a beneficial outcome, and significantly decreases the incidence and severity of vasculitis. The role of autophagy in VSMCs appears of high interest, given that there is currently no effective therapy aimed at specifically targeting LMP formation or addressing the long-term KD vascular lesions in KD patients. Impaired autophagy/mitophagy results in uncontrolled activation of the NLRP3 inflammasome and production of IL-1β. Enhancing this pathway pharmacologically, either with MN58b or Metformin, effectively prevented the development of LCWE-induced cardiovascular lesions, such as heart inflammation and AAA, by downregulating the NLRP3-IL-1β pathway. Therefore, pharmacological modulation of autophagy is a potentially interesting target and could provide an alternative to treat IVIG-resistant KD patients and prevent long-term cardiovascular lesions.
MATERIALS AND METHODS

**Experimental Animals.** Wild-type (WT) C57BL/6 and Myh11cre/ERT2 (B6.FVB-Tg(Myh11-cre/ERT2)1Soff/J) mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Parkin−/− and Ogg1−/− mice were a kind gift from Dr. Gottlieb (Cedars-Sinai Medical Center) and Dr. Christi A. Walter (University of Texas Health Science Center at San Antonio), respectively. Experimental Parkin−/− and Ogg1−/− mice were obtained from homozygous breeding, and age-matched WT C57BL/6J from our internal colony at Cedars-Sinai were used as controls. LysMCre Atg16l1Δ/Δ mice were obtained from Dr. David Shih at Cedars Sinai Medical Center (73). Littermate Atg16l1fl/fl mice were used as controls. Atg16l1fl/fl mice were also crossed with Myh11cre/ERT2 to generate Myh11cre/ERT2 Atg16l1Δ/Δ with a tamoxifen-induced specific deletion of Atg16l1 in vascular smooth muscle cells (VSMCs). Mice were housed under specific pathogen-free conditions and used according to the guidelines of the Cedars-Sinai Medical Center institutional committee.

**LCWE-induced murine model of KD vasculitis.** *Lactobacillus casei* (ATCC 11578) cell wall extract (LCWE) was prepared in our laboratory as previously described (28). 5-week-old male mice were injected with a single dose of 500μg of LCWE or PBS intraperitoneally (i.p.). One or two weeks after the injection, depending on the experimental design, mice were euthanized, blood and heart tissues were harvested for analysis. Abdominal aorta tissues were photographed prior embedding in Tissue-Tek OCT Compound and the maximal aorta diameter and the abdominal aorta area were measured in Image J. The upper 2/3 of heart tissues (exempt the apex) and the abdominal aorta were embedded in OCT for further immunohistochemistry analysis. Serial cryosections (7µm) from all hearts and abdominal aortas were generated for histology. Histopathological examination and inflammation severity scoring of the coronary arteries, aortic root vasculitis, and myocarditis were performed on Hematoxylin & Eosin (H&E) stained sections by two senior investigators blinded to the experimental groups. In experiments involving
Myh11cre/ERT2Atg16fl/flΔ/Δ mice, Atg16fl/fl and Myh11cre/ERT2Atg16Δ/Δ male mice were fed a Tamoxifen diet for 2 consecutive weeks beginning at the age of 3 weeks. Mice were left to rest for the following 4 weeks and LCWE injection was performed at the age of 9 weeks. The mice were euthanized, and tissues harvested one week after LCWE injection.

**Pharmacological modulation of autophagy.** Metformin Hydrochloride (Fisher Scientific, #NC0552835) was injected daily i.p. at a dose of 300mg/kg of body weight beginning 2 days before LCWE injection until day 7 post-LCWE-injection (74). To block autophagy, 10mg/kg of body weight of Chloroquine (CQ) diphosphate salt (Sigma-Aldrich, #C6628) were injected i.p. every other day, beginning one day before LCWE injection until day 7 post-LCWE (32). For experiments involving intermittent fasting, food was removed from the cages for a period of 24h every other day, beginning on the day of LCWE injection until day 7 post-LCWE injection, when tissues were harvested (27). Mice body weights were measured daily and no significant changes throughout the experiment were observed between the intermittently fasted and control mice (Supplementary Figure 1A). The animals had access to water ad libidum. Mitoquinone mesylate (MitoQ) (MedKoo, #317102) was injected i.p. daily at a dose of 5mg/kg of body weight starting the day before LCWE injection until day 7, when tissues were harvested (75). MN58b, a choline kinase α inhibitor (provided by Dr. Karin, UCSD, California), was injected i.p. daily at a dose of 2.5mg/kg of body weight beginning 2 days before LCWE injection until day 7, when tissues were harvested (48).

**Western blot analysis.** Whole lysate and mitochondrial fractions for Western blots were prepared from fresh heart tissue as previously published (25). Membranes were incubated with the following antibodies: microtubule-associated proteins 1A/1B light chain 3B (LC3) (Cell Signaling
Technology #12741S), S6 (Cell Signaling Technology #2217S), phospho-S6 (Ser 235/236) (Cell Signaling Technology #4858T), p62/SQSTM1 (Abcam #ab56416), oxphos cocktail (Abcam #ab110413), autophagy related gene (ATG) 5 (Cell Signaling Technology,#12994T), Parkin (Santa Cruz Biotechnology #sc-32282), phospho-ubiquitin (Ser65) (EMD Millipore, #ABS1513-I), Unc-51 like autophagy activating kinase (ULK-1) (Cell Signaling Technology, #8054T), phospho-ULK-1 (Ser555) (Cell Signaling Technology, #5869), mitochondrial fission factor (MFF) (Cell Signaling Technology, #84580), phospho-C2orf33 (pMFF) (Ser172, Ser146) (Thermo-Fisher Scientific, #PA5-104614), optic atrophy 1 (OPA1) (Cell Signaling Technology, #80471S), Dynamin-related protein 1 (DPR1) (Cell Signaling Technology, #8570S), phospho-DRP1 (Ser616) (Cell Signaling Technology, #4494S), AMP-activated protein kinase alpha (AMPKα) (Cell Signaling Technology, #2603S), phospho-AMPKα (Thr172) (Cell Signaling Technology, #2531).

All antibodies were used in a 1:1000 dilution prepared in either 0.5% milk or bovine serum albumin (BSA). All proteins were normalized either to GAPDH (Cell Signaling Technology, #5174S), COX IV (Santa Cruz Biotechnology, #376731) or ponceau (Sigma-Aldrich, St. Louis, MI, USA). Quantification was performed with the Software Image Lab (BioRad).

**In vivo autophagic flux assay.** To quantify autophagic flux, mice were injected i.p. with a single dose of CQ at 40mg/kg of body weight on day 7 after LCWE injection. Four hours after CQ injection, heart and abdominal aorta tissues were collected and processed for Western blot analysis. Membranes were incubated with LC3. To assess in vivo autophagic flux, each experimental treatment comprised a CQ and non-CQ treated arm. Accumulation of LC3-II in heart tissues of CQ treated mice was compared to LC3-II levels observed in heart tissues of control non-CQ-injected mice. Higher LC3-II accumulation in heart tissues, assessed as the ratio of LC3-II in the CQ vs non-CQ-injected mice, indicated increased autophagic flux (32, 33).
**Single-cell RNA sequencing of abdominal aortas.** Expression of genes related to the autophagy and mitophagy pathways was assessed on a publicly available single-cell RNA sequencing dataset generated from the abdominal aortas of PBS and LCWE-injected mice (GSE178765) (39). UMAP projections were performed using the R package *umap* v0.2.2.0 (76), cell clustering and annotations were done with Seurat V3 and SingleR (39).

**Dihydroethidium (DHE) staining for ROS measurement.** Frozen sections of abdominal aorta tissue were stained with DHE to quantify ROS production, as previously published (77). 5 fields of equal size were randomly selected in each tissue section and the integrated density of the signal was calculated with the software Image J.

**FAM-FLICA® Caspase assay.** Caspase-1 activity was measured on frozen sections of heart tissue by FAM-FLICA® Caspase assay (ImmunoChemistry Technologies, #98) as previously published (11).

**ELISA.** Serum levels of 8-OHdG were quantified with the 8-hydroxy 2 deoxyguanosine ELISA kit (Abcam, #ab201734) according to the manufacturer’s instructions. IL-1β was measured in serum using the V-PLEX Mouse IL-1β Kit (Meso Scale Diagnostics, #K152QPD-1) per the manufacturer’s instructions. The samples were read and analyzed by MSD QuickPlex SQ120 instrumentation and Workbench 4.0 Software (Meso Scale Diagnostics).
Proteomics analysis of abdominal aorta tissues with MitoPlex. Mitochondrial proteins of snap frozen abdominal aorta tissues were analyzed with a tier 2 level, targeted proteomic analysis as previously published (44).

Mitochondrial respirometry assay. Mitochondria were isolated from fresh heart tissue whole lysate as previously described (78), and mitochondrial respirometry assay was performed using a Seahorse XF Cell Mito Stress Test Kit (Agilent #103015-100, Santa Clara, CA, USA) according to the manufacturer’s instructions. XFe96 well plates were loaded in port A with ADP (0.25 mM final concentration), pyruvate (10mM final concentration) and malate (2mM final concentration), port B with oligomycin (2µM final concentration), port C with carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, 2µM final concentration), and port D with antimycin A/rotenone (1µM final concentration for each). The data were acquired with a Seahorse XFe96 Analyzer (Agilent Technologies, Santa Clara, CA, USA) and further on analyzed with the software WAVE (Agilent Technologies, Santa Clara, CA, USA). The data were normalized to total mitochondrial protein content.

Statistical analysis. Data were analyzed with GraphPad Prism (GraphPad Software, CA) and are presented as mean ± SEM. Statistical outliers were identified using the Grubbs’ test with a significance level of 0.05. Results were considered statistically significant with a p-value < 0.05. Normality was tested with the Shapiro-Wilk normality test. For 2 groups comparisons of normally distributed data, two-tailed unpaired Student t-test, with Welch’s correction when indicated, were used. For non-parametric data, the Mann-Whitney U test was used. For multiple comparison testing, significance was evaluated by 1- or 2-way ANOVA with Tukey’s post-test analysis. All data in this manuscript were acquired by at least two independent experiments.
Study approval. All animal studies in this manuscript were approved by the Institutional Animal Care and Use Committee (IACUC) of Cedars Sinai Medical Center and were performed in accordance with the National Institutes of Health (NIH) Guidelines for the Care and Use of Laboratory Animals.

AUTHOR CONTRIBUTIONS

Conceptualization: S.M.I., T.R.C., M.N.R. and M. Arditi. Investigation: S.M.I., A.B.O., D.M., M.L., A.C.G., R.A.P., Y.L., M.A., A.S., S.P. performed experiments and K.S., T.R.C., M.N.R and M. Arditi supervised experiments. Data analysis: S.M.I., R.A.P., M.A., A.S., S.P., D.Z. and M.C.F. Data discussion: S.I.M., R.A.P., D.Z., T.R.C., K.S., E.S-L., J.V.E., R.A.G., M.K., M.N.R. and M. Arditi. Manuscript writing: S.M.I., T.R.C., M.N.R. and M. Arditi.

ACKNOWLEDGEMENTS

We would like to thank the members of the Arditi laboratory for their technical support.

SOURCE OF FUNDING

We gratefully acknowledge support from the NIH awards R01 AI072726 and 3RO1AI072726-10S1 (to MA)
REFERENCES

1. Soni PR, Noval Rivas M, and Arditi M. A Comprehensive Update on Kawasaki Disease Vasculitis and Myocarditis. *Curr Rheumatol Rep.* 2020;22(2):6.

2. Kato H, Koike S, Yamamoto M, Ito Y, and Yano E. Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. *J Pediatr.* 1975;86(6):892-8.

3. Newburger JW, Takahashi M, and Burns JC. Kawasaki Disease. *J Am Coll Cardiol.* 2016;67(14):1738-49.

4. Burns JC. Kawasaki Disease update. *Indian J Pediatr.* 2009;76(1):71-6.

5. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association. *Circulation.* 2017;135(17):e927-e99.

6. Gordon JB, Kahn AM, and Burns JC. When children with Kawasaki disease grow up: Myocardial and vascular complications in adulthood. *J Am Coll Cardiol.* 2009;54(21):1911-20.

7. Brogan P, Burns JC, Cornish J, Diwakar V, Eleftheriou D, Gordon JB, et al. Lifetime cardiovascular management of patients with previous Kawasaki disease. *Heart.* 2020;106(6):411-20.

8. Lee Y, Schulte DJ, Shimada K, Chen S, Crother TR, Chiba N, et al. Interleukin-1beta is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. *Circulation.* 2012;125(12):1542-50.

9. Noval Rivas M, Lee Y, Wakita D, Chiba N, Dagvadorj J, Shimada K, et al. CD8+ T Cells Contribute to the Development of Coronary Arteritis in the Lactobacillus casei Cell Wall Extract-Induced Murine Model of Kawasaki Disease. *Arthritis Rheumatol.* 2017;69(2):410-21.

10. Porritt RA, Markman JL, Maruyama D, Kocaturk B, Chen S, Lehman TJA, et al. Interleukin-1Beta-Mediated Sex Differences in Kawasaki Disease Vasculitis Development and Response to Treatment. *Arterioscler Thromb Vasc Biol.* 2020;40(3):802-18.

11. Wakita D, Kurashima Y, Crother TR, Noval Rivas M, Lee Y, Chen S, et al. Role of Interleukin-1 Signaling in a Mouse Model of Kawasaki Disease-Associated Abdominal Aortic Aneurysm. *Arterioscler Thromb Vasc Biol.* 2016;36(5):886-97.

12. Maury CP, Salo E, and Pelkonen P. Circulating interleukin-1 beta in patients with Kawasaki disease. *N Engl J Med.* 1988;319(25):1670-1.

13. Senzaki H. The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases. *Arch Dis Child.* 2006;91(10):847-51.

14. Weng KP, Hsieh KS, Ho TY, Huang SH, Lai CR, Chiu YT, et al. IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease. *Circ J.* 2010;74(3):544-51.

15. Alphonse MP, Duong TT, Shumitzu C, Hoang TL, McCrindle BW, Franco A, et al. Inositol-Trisphosphate 3-Kinase C Mediates Inflammamosome Activation and Treatment Response in Kawasaki Disease. *J Immunol.* 2016;197(9):3481-9.

16. Shires SE, and Gustafsson ÅB. Mitophagy and heart failure. *J Mol Med (Berl).* 2015;93(3):1812-24.

17. Yang Z, and Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. *Curr Opin Cell Biol.* 2010;22(2):124-31.

18. Bravo-San Pedro JM, Kroemer G, and Galluzzi L. Autophagy and Mitophagy in Cardiovascular Disease. *Circ Res.* 2017;120(11):1812-24.

19. Sciarretta S, Maejima Y, Zablocki D, and Sadoshima J. The Role of Autophagy in the Heart. *Annu Rev Physiol.* 2018;80:1-26.

20. Galluzzi L, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cecconi F, et al. Molecular definitions of autophagy and related processes. *Embo J.* 2017;36(13):1811-36.
21. Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, Chen S, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. *Immunity*. 2012;36(3):401-14.

22. Tumurkhuu G, Shimada K, Dagvadorj J, Crother TR, Zhang W, Luthringer D, et al. Ogg1-Dependent DNA Repair Regulates NLRP3 Inflammasome and Prevents Atherosclerosis. *Circ Res*. 2016;119(6):e76-90.

23. Li Y, Liang P, Jiang B, Tang Y, Liu X, Liu M, et al. CARD9 promotes autophagy in cardiomyocytes in myocardial ischemia/reperfusion injury via interacting with Rubicon directly. *Basic Res Cardiol*. 2020;115(3):29.

24. Morciano G, Patergnani S, Bonora M, Pedriali G, Tarocco A, Bouhamida E, et al. Mitophagy in Cardiovascular Diseases. *J Clin Med*. 2020;9(3).

25. Marek-Iannucci S, Thomas A, Hou J, Crupi A, Sin J, Taylor DJ, et al. Myocardial hypothermia increases autophagic flux, mitochondrial mass and myocardial function after ischemia-reperfusion injury. *Sci Rep*. 2019;9(1):10001.

26. Sasaki Y, Ikeda Y, Iwabayashi M, Akasaki Y, and Ohishi M. The Impact of Autophagy on Cardiovascular Senescence and Diseases. *Int Heart J*. 2017;58(5):666-73.

27. Godar RJ, Ma X, Liu H, Murphy JT, Weinheimer CJ, Kovacs A, et al. Repetitive stimulation of autophagy-lysosome machinery by intermittent fasting preconditions the myocardium to ischemia-reperfusion injury. *Autophagy*. 2015;11(9):1537-60.

28. Lee Y, Schulte DJ, Shimada K, Chen S, Crother TR, Chiba N, et al. Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. *Circulation*. 2012;125(12):1542-50.

29. Lee Y, Wakita D, Dagvadorj J, Shimada K, Chen S, Huang G, et al. IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model: Role of Both IL-1α and IL-1β. *Arterioscler Thromb Vasc Biol*. 2015;35(12):2605-16.

30. Biasizzo M, and Kopitar-Jerala N. Interplay Between NLRP3 Inflammasome and Autophagy. *Front Immunol*. 2020;11:591803.

31. Kim J, Kundu M, Viollet B, and Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat Cell Biol*. 2011;13(2):132-41.

32. Gottlieb RA, Andres AM, Sin J, and Taylor DP. Untangling autophagy measurements: all fluxed up. *Circ Res*. 2015;116(3):504-14.

33. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1). *Autophagy*. 2021;17(1):1-382.

34. Crother TR, Porritt RA, Dagvadorj J, Tumurkhuu G, Slepenkin AV, Peterson EM, et al. Autophagy Limits Inflammasome During Chlamydia pneumoniae Infection. *Front Immunol*. 2019;10:754.

35. Ramadan A, Al-Omran M, and Verma S. The putative role of autophagy in the pathogenesis of abdominal aortic aneurysms. *Atherosclerosis*. 2017;257:288-96.

36. Zheng YH, Tian C, Meng Y, Qin YW, Du YH, Du J, et al. Osteopontin stimulates autophagy via integrin/CD44 and p38 MAPK signaling pathways in vascular smooth muscle cells. *J Cell Physiol*. 2012;227(1):127-35.

37. Salmon M, Spinosa M, Zehner ZE, Upchurch GR, and Ailawadi G. Klf4, Klf2, and Zfp148 activate autophagy-related genes in smooth muscle cells during aortic aneurysm formation. *Physiol Rep*. 2019;7(8):e14058.

38. Clément M, Chappell J, Raffort J, Lareyre F, Vandestienne M, Taylor AL, et al. Vascular Smooth Muscle Cell Plasticity and Autophagy in Dissecting Aortic Aneurysms. *Arterioscler Thromb Vasc Biol*. 2019;39(6):1149-59.

39. Rebecca A. Porrit DZ, Masanori Abe, Youngho Lee, Meena Narayanan, Thacyana Teixeira de Carvalho, Angela C. Gomez, Chintda Santiskulvong, Michael C. Fishbein, Shuang Chen, Timothy
R. Crother, Kenichi Shimada, Moshe Arditi, Magali Noval Rivas. Single-cell and spatial transcriptomics reveal NLRP3 inflammasome-mediated immune-stromal interactions during vasculitis and cardiovascular inflammation. *Circulation Research under review.* 2021.

40. Vásquez-Trincado C, García-Carvajal I, Pennanen C, Parra V, Hill JA, Rothermel BA, et al. Mitochondrial dynamics, mitophagy and cardiovascular disease. *J Physiol.* 2016;594(3):509-25.

41. Bonora M, Wieckowski MR, Sinclair DA, Kroemer G, Pinton P, and Galluzzi L. Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles. *Nat Rev Cardiol.* 2019;16(1):33-55.

42. Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M, et al. Ubiquitin is phosphorylated by PINK1 to activate parkin. *Nature.* 2014;510(7503):162-6.

43. Barazzuol L, Giamogante F, Brini M, and Calì T. PINK1/Parkin Mediated Mitophagy, Ca(2+) Signalling, and ER-Mitochondria Contacts in Parkinson’s Disease. *Int J Mol Sci.* 2020;21(5).

44. Stotland AB, Spivia W, Orosco A, Andres AM, Gottlieb RA, Van Eyk JE, et al. MitoPlex: A targeted multiple reaction monitoring assay for quantification of a curated set of mitochondrial proteins. *J Mol Cell Cardiol.* 2020;142:1-13.

45. Wirth C, Brandt U, Hunte C, and Zickermann V. Structure and function of mitochondrial complex I. *Biochim Biophys Acta.* 2016;1857(7):902-14.

46. Mills EL, Kelly B, and O’Neill LAJ. Mitochondria are the powerhouses of immunity. *Nat Immunol.* 2017;18(5):488-98.

47. de Souza-Pinto NC, Eide L, Hogue BA, Thybo T, Stevnsner T, Seeberg E, et al. Repair of 8-oxodeoxyguanosine lesions in mitochondrial dna depends on the oxoguanine dna glycosylase (OGG1) gene and 8-oxoguanine accumulates in the mitochondrial dna of OGG1-defective mice. *Cancer Res.* 2001;61(14):5378-81.

48. Sanchez-Lopez E, Zhong Z, Stubelius A, Sweeney SR, Booshehri LM, Antonucci L, et al. Choline Uptake and Metabolism Modulate Macrophage IL-1β and IL-18 Production. *Cell Metab.* 2019;29(6):1350-62.e7.

49. Valavanidis A, Vlachogianni T, and Fiotakis C. 8-hydroxy-2'-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev.* 2009;27(2):120-39.

50. Foretz M, Guigas B, Bertrand L, Pollak M, and Viollet B. Metformin: from mechanisms of action to therapies. *Cell Metab.* 2014;20(6):953-66.

51. Mohsin AA, Chen Q, Quan N, Rousselle T, Maceyka MW, Samidurai A, et al. Mitochondrial Complex I Inhibition by Metformin Limits Reperfusion Injury. *J Pharmacol Exp Ther.* 2019;369(2):282-90.

52. Wang Y, An H, Liu T, Qin C, Sesaki H, Guo S, et al. Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK. *Cell Rep.* 2019;29(6):1511-23.e5.

53. Lu M, Su C, Qiao C, Bian Y, Ding J, and Hu G. Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS Clearance. *Int J Neuropsychopharmacol.* 2016;19(9).

54. Bagherniya M, Butler AE, Barreto GE, and Sahebkar A. The effect of fasting or calorie restriction on autophagy induction: A review of the literature. *Ageing Res Rev.* 2018;47:183-97.

55. Gottlieb RA, and Mentzer RM. Autophagy during cardiac stress: joys and frustrations of autophagy. *Annu Rev Physiol.* 2010;72:45-59.

56. Sun Q, Fan J, Billiar TR, and Scott MJ. Inflammasome and autophagy regulation - a two-way street. *Mol Med.* 2017;23:188-95.

57. Deretic V, Saitoh T, and Akira S. Autophagy in infection, inflammation and immunity. *Nat Rev Immunol.* 2013;13(10):722-37.
58. Levine B, Mizushima N, and Virgin HW. Autophagy in immunity and inflammation. *Nature*. 2011;469(7330):323-35.

59. Nowarski R, Jackson R, and Flavell RA. The Stromal Intervention: Regulation of Immunity and Inflammation at the Epithelial-Mesenchymal Barrier. *Cell*. 2017;168(3):362-75.

60. Wang X, Luo G, Zhang K, Cao J, Huang C, Jiang T, et al. Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis. *Cancer Res*. 2018;78(16):4586-98.

61. Zhang Y, Wang Y, Zhang L, Xia L, Zheng M, Zeng Z, et al. Reduced Platelet miR-223 Induction in Kawasaki Disease Leads to Severe Coronary Artery Pathology Through a miR-223/PDGFRβ Vascular Smooth Muscle Cell Axis. *Circ Res*. 2020;127(7):855-73.

62. Chistiakov DA, Shkurat TP, Melnichenko AA, Grechko AV, and Orekhov AN. The role of mitochondrial dysfunction in cardiovascular disease: a brief review. *Ann Med*. 2018;50(2):121-7.

63. Huang FC, Huang YH, Kuo HC, and Li SC. Identifying Downregulation of Autophagy Markers in Kawasaki Disease. *Children (Basel)*. 2020;7(10).

64. Niedra E, Chahal N, Manhiot C, Yeung RS, and McCrindle BW. Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms. *Pediatr Cardiol*. 2014;35(1):89-92.

65. Tremoulet AH, Jain S, Jone PN, Best BM, Duxbury EH, Franco A, et al. Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm. *J Pediatr*. 2019;215:107-17.e12.

66. Peng S, Xu LW, Che XY, Xiao QQ, Pu J, Shao Q, et al. Atorvastatin Inhibits Inflammatory Response, Attenuates Lipid Deposition, and Improves the Stability of Vulnerable Atherosclerotic Plaques by Modulating Autophagy. *Front Pharmacol*. 2018;9:438.

67. Andres AM, Hernandez G, Lee P, Huang C, Ratliff EP, Sin J, et al. Mitophagy is required for acute cardioprotection by simvastatin. *Antioxid Redox Signal*. 2014;21(14):1960-73.

68. Xiao L, Xu X, Zhang F, Wang M, Xu Y, Tang D, et al. The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PINK1. *Redox Biol*. 2017;11:297-311.

69. Tsuji G, Hashimoto-Hachiya A, Yen VH, Takemura M, Yumine A, Furue K, et al. Metformin inhibits IL-1β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis. *Cell Death Discov*. 2020;6:11.

70. Yang F, Qin Y, Wang Y, Meng S, Xian H, Che H, et al. Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy. *Int J Biol Sci*. 2019;15(5):1010-9.

71. Huang SM, Weng KP, Chang JS, Lee WY, Huang SH, and Hsieh KS. Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease: a pilot study. *Circ J*. 2008;72(10):1583-7.

72. Wei YM, Li X, Xu M, Abais JM, Chen Y, Riebling CR, et al. Enhancement of autophagy by simvastatin through inhibition of Rac1-mTOR signaling pathway in coronary arterial myocytes. *Cell Physiol Biochem*. 2013;31(6):925-37.

73. Zhang H, Zheng L, McGovern DP, Hamill AM, Ichikawa R, Kanazawa Y, et al. Myeloid ATG16L1 Facilitates Host-Bacteria Interactions in Maintaining Intestinal Homeostasis. *J Immunol*. 2017;198(5):2133-46.

74. Kinaan M, Ding H, and Triggle CR. Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. *Med Princ Pract*. 2015;24(5):401-15.

75. Santini E, Turner KL, Ramaraj AB, Murphy MP, Klann E, and Kaphzan H. Mitochondrial Superoxide Contributes to Hippocampal Synaptic Dysfunction and Memory Deficits in Angelman Syndrome Model Mice. *J Neurosci*. 2015;35(49):16213-20.
Becht E, McInnes L, Healy J, Dutertre CA, Kwok IWH, Ng LG, et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat Biotechnol. 2018.

Wang Q, and Zou MH. Measurement of Reactive Oxygen Species (ROS) and Mitochondrial ROS in AMPK Knockout Mice Blood Vessels. Methods Mol Biol. 2018;1732:507-17.

Rogers GW, Brand MD, Petrosyan S, Ashok D, Elorza AA, Ferrick DA, et al. High throughput microplate respiratory measurements using minimal quantities of isolated mitochondria. PLoS One. 2011;6(7):e21746.
Figure 1

A. Heart vessel inflammation score

B. Aorta area (cm²)

C. IL-1β pg/mL

D. mTOR axis

E. S6/GAPDH

F. ULK1/GAPDH

G. AMPK/GAPDH

H. p62/GAPDH

I. LC3-I/LC3-II ratio/GAPDH

J. LC3-I/LC3-II/GAPDH
Figure 1. Autophagic flux is impaired during LCWE-induced KD vasculitis. (A) H&E stained heart tissue sections and heart vessel inflammation score from PBS and LCWE-injected mice, one week post-LCWE injection (n=5/group). Scale bars: 500µm. (B) Representative pictures of the abdominal aorta, maximal abdominal aorta diameter and abdominal aorta area measurements from PBS and LCWE-injected mice at one week post-LCWE injection (n=5/group). (C) Systemic IL-1β levels in the serum of PBS and LCWE-injected mice, at one week post-LCWE injection (n=5/group). (D, E) Western Blot (WB) analysis (D) and quantification (E) of mTOR-axis related proteins in whole lysate heart tissues from PBS and LCWE-injected mice, one week post-LCWE injection with (n=5/group). (F, G) Western Blot (WB) images (F) and quantification (G) of AMPK-axis related proteins in whole lysate heart tissues from PBS and LCWE-injected mice, one week post-LCWE injection with (n=5/group). (H, I) Western blot analysis (H) and quantification (I) of autophagy related proteins in whole lysate heart tissues from PBS and LCWE-injected mice, one week post-LCWE injection with (n=5/group). (J) In vivo autophagic flux assay, measured by Western Blot analysis and quantification of LC3-II protein accumulation in whole lysate heart tissue from WT PBS and LCWE treated mice, one week post LCWE injection and a single dose of 40mg/kg Chloroquine (CQ) i.p. 4h prior to tissue harvest (n=5/group). *p<0.05, **p<0.01, ***p<0.001 by Mann-Whitney U test (pS6 Fig. 1E, pAMPK/AMPK Fig. 1G), 2-way ANOVA with Tukey’s post-test analysis (Fig. 1J) and unpaired Student t test for all other panels.
Figure 2

A. LCWE and LCWE+fasting

|   | LCWE | LCWE+fasting |
|---|------|--------------|
| 1 | p62  |              |
| 2 | LC3-I|              |
| 3 | LC3-II|             |
| 4 | GAPDH|              |
| 5 |      |              |

B. LCWE and LCWE+fasting

|   | LCWE | LCWE+fasting |
|---|------|--------------|
| 0 | p2GAPDH |              |
| 1 |          |              |
| 2 |          |              |

C. LCWE and Fasting

|   | no-CQ | CQ |
|---|-------|----|
| 1 |       |    |
| 2 |       |    |
| 3 |       |    |

D. LCWE and LCWE+fasting

|   | LCWE | LCWE+fasting |
|---|------|--------------|
| 0 | Heart vessel inflammation score |
| 1 |                            |
| 2 |                            |
| 3 |                            |

E. LCWE and LCWE+fasting

|   | LCWE | LCWE+fasting |
|---|------|--------------|
| 0 | Aorta area (cm²) |
| 1 |          |              |
| 2 |          |              |

F. LCWE and LCWE+fasting

|   | LCWE | LCWE+fasting |
|---|------|--------------|
| 0 | FLC/APE |
| 1 |        |              |
| 2 |        |              |
| 3 |        |              |

G. LCWE and LCWE+fasting

|   | LCWE | LCWE+fasting |
|---|------|--------------|
| 0 | InB p/mL |
| 1 |        |              |
| 2 |        |              |

H. LCWE and LCWE+CQ

|   | LCWE | LCWE+CQ |
|---|------|--------|
| 0 | Heart vessel inflammation score |
| 1 |                            |
| 2 |                            |
| 3 |                            |

I. LCWE and LCWE+CQ

|   | LCWE | LCWE+CQ |
|---|------|--------|
| 0 | Aorta area (cm²) |
| 1 |          |        |
| 2 |          |        |
| 3 |          |        |
Figure 2. Increase of autophagic flux reduces the development of LCWE-induced cardiovascular lesions. (A, B) Western blot images (A) and quantification (B) of p62, LC3 and GAPDH in whole lysate from heart tissue of LCWE-injected mice and fasted LCWE-injected mice, one week post-LCWE injection (n=5/group). (C) Representative image of western blot analysis detecting LC3-I, LC3-II and GAPDH (n=3/group; left) and LC3-II/GAPDH quantification (n=5-7/group; right) in heart tissue whole lysates from non-fasted and intermittently fasted mice at one week post LCWE-injection and 4 hours after a single dose of Chloroquine (CQ) (n=5-7/group). (D) H&E staining of heart sections and heart vessel inflammation score of non-fasted and intermittently fasted mice at one week post-LCWE injection (n=10/group). Scale bars: 500µm. (E) Representative pictures of the abdominal aorta, aorta area measurements and maximal aorta diameter of non-fasted and intermittently fasted LCWE-injected mice at one week post-LCWE injection (n=10/group). (F) FLICA staining and FLICA quantification in heart tissues from non-fasted and intermittently fasted LCWE-injected mice, one week post-LCWE injection. White arrows indicate FLICA positive cells (n=5/group; scale: 100µm). (G) Systemic IL-1β levels of non-fasted and intermittently fasted LCWE-injected mice, one week post-LCWE injection (n=4-5/group). (H) H&E staining of heart tissue sections and heart inflammation score from LCWE injected mice and LCWE-injected mice treated with CQ, one week post-LCWE injection (n=9-10/group). (I) Representative pictures of the abdominal aorta, aorta area measurements and maximal abdominal aorta diameter of LCWE injected mice and LCWE-injected mice treated with CQ at one week post-LCWE injection (n=9-10/group). *p<0.05, **p<0.01, ***p<0.001 by Mann-Whitney U test (Fig. 2D, 2I), 2-way ANOVA with Tukey’s post-test analysis (Fig. 2C) and unpaired Student t test for all other panels.
Figure 3

A

LysM Cre

LoxP

Atg16l1 LoxP

B

Atg16l1 Δ/Δ

LyzM Cre/ERT2 Atg16l1 Δ/Δ

Heart vessel inflammation score

C

Atg16l1 Δ/Δ

LyzM Cre

Atg16l1 Δ/Δ

Max. aorta diameter (mm)

Aorta area (cm²)

D

Myh11 Cre

LoxP

Atg16l1 LoxP

Tamoxifen diet

LCWE

Sac.

E

Atg16l1 Δ/Δ

Myh11 Cre/ERT2 Atg16l1 Δ/Δ

Heart vessel inflammation score

F

Atg16l1 Δ/Δ

Myh11 Cre/ERT2 Atg16l1 Δ/Δ

Max. aorta diameter (mm)

Aorta area (cm²)
Figure 3. Specific deletion of *Atg16l1* in smooth muscle cells increases the severity of LCWE-induced KD vasculitis. (A) Schematic representation of the experimental design. *Atg16*<sup>fl/fl</sup> mice were crossed with *LyzM<sup>cre</sup>* mice to generate *LyzM<sup>cre</sup>* *Atg16Δ/Δ* mice with a specific deletion of *Atg16l1* in myeloid cells. (B) Heart sections H&E staining and heart vessel inflammation score of *Atg16*<sup>fl/fl</sup> (n=8) and *LyzM<sup>cre</sup>* *Atg16Δ/Δ* mice (n=10) injected with LCWE at one week post-injection. (C) Representative pictures of the abdominal aorta, maximal aorta diameter and abdominal aorta area measurements of LCWE-injected *Atg16*<sup>fl/fl</sup> and *LyzM<sup>cre</sup>* *Atg16Δ/Δ* mice one-week post-LCWE injection (n=8-10/group). (D) Schematic representation of the experimental design. *Atg16*<sup>fl/fl</sup> mice and *Myh11<sup>cre/ERT2</sup>* *Atg16Δ/Δ* mice received a tamoxifen diet for 2 weeks, were rested for 4 weeks and on week 5 received an injection of LCWE. (E) Heart sections H&E staining and heart vessel inflammation score of *Atg16*<sup>fl/fl</sup> mice and *Myh11<sup>cre/ERT2</sup>* *Atg16Δ/Δ* mice that were injected with LCWE one-week post-injection (n=5-7/group). (F) Representative pictures of the abdominal aorta, maximal aorta diameter and aorta area measurement, of LCWE-injected *Atg16*<sup>fl/fl</sup> and *Myh11<sup>cre/ERT2</sup>* *Atg16Δ/Δ* mice one week post-LCWE injection (n=5-7/group). *p<0.05, **p<0.01, ***p<0.001 by unpaired Student t tests.
Figure 4. LCWE-induced KD vasculitis is associated with impaired mitophagy. (A, B) Western Blot analysis (A) and quantification (B) of mitophagy related proteins in mitochondrial fractions of heart tissues from PBS and LCWE-injected mice, one week post-LCWE injection (n=5/group). (C, D) Western blot analysis (C) and quantification (D) of complex I (CI), CII, CIII and CV reflecting mitochondrial content, in whole lysates of heart tissues collected from PBS and LCWE-injected mice, one week post-LCWE injection (n=5/group). (E) Oxygen consumption rate (OCR) measurements of freshly isolated mitochondria from heart tissue whole lysates of PBS and LCWE-injected mice, one week post-LCWE injection (n=5/group, representative experiment shown out of 3). Vertical lines indicate the timepoints where oligomycin, FCCP and Rotenone/Antimycin A were added. ADP and FCCP OCR rates shown to the right represent the cumulative of three experiments. (F) Heart sections H&E staining and heart vessel inflammation score of LCWE-injected WT (n=10) and Parkin−/− (n=8) mice one week post-LCWE injection. Scale bars: 500µm. (G) Representative pictures of the abdominal aorta, maximal abdominal aorta diameter and abdominal aorta area from WT and Parkin−/− mice two weeks post-LCWE injection (n=8-10/group). (H) Heatmap of mitochondrial protein (log2 fold change) expression obtained by MitoPlex analysis of the abdominal aorta tissue of LCWE-injected WT mice and LCWE-injected WT mice intermittently fasted, at one week after LCWE injection (n=5/group). (I) Principal component analysis (PCA) of mitochondrial proteins by MitoPlex analysis in the abdominal aorta tissue of PBS, LCWE injected intermittently fasted LCWE-injected mice, one week after LCWE injection (n=5/group). *p<0.05, **p<0.01, ***p<0.001 by unpaired Student t tests.
Figure 5

A

B

C

D

E

F

G

H

I

J
Figure 5. ROS and oxidative DNA damage activate NLRP3 and influence cardiovascular lesion formation. (A) 8OHdg levels measured in serum of PBS or LCWE-injected WT mice one week after injection (n=9-11/group). (B) Representative Dihydroethidium (DHE) staining and ROS quantification in frozen abdominal aorta tissues cross-sections collected from WT mice injected with either PBS or LCWE one week post-injection (n=5-6/group; Scale bars: 100µm). (C) Heart sections H&E staining and heart vessel inflammation score of LCWE-injected WT (n=8) and Ogg1−/− mice (n=9) one week post-LCWE injection. Scale bars: 500µm (D) Representative pictures of the abdominal aorta, maximal aorta diameter and abdominal aorta area measurements from LCWE-injected WT (n=8) and Ogg1−/− (n=9) mice at one week post-injection. (E) FLICA staining and quantification in frozen heart tissue sections of LCWE-injected mice and LCWE-injected fasted mice at one week post-LCWE injection (n=5/group). White arrows indicate FLICA positive cells. Scale bars; 100µm. (F) Representative DHE staining and ROS quantification in abdominal aorta tissues cross-sections from LCWE-injected WT and Ogg1−/− mice, one-week post-injection (n=7/group, scale: 100µm). (G) Heart sections H&E staining and heart vessel inflammation score of WT mice injected with LCWE or WT mice injected with LCWE and MitoQ one week post-LCWE injection (n=10/group, Scale bars: 500µm). (H) Representative pictures of the abdominal aorta area, maximal aorta diameter and measurements of the abdominal aorta area from LCWE-injected WT mice and WT mice injected with LCWE and MitoQ one week post-LCWE injection (n=10/group). (I) Representative DHE staining and ROS quantification in abdominal aorta tissues cross-sections collected from WT mice injected with LCWE or WT mice injected with LCWE and MitoQ one week after injection (n=5/group, scale: 100µm). (J) 8OHdg levels measured in the serum of WT mice treated with LCWE+PBS or LCWE + MitoQ one week after injection (n=5-7/group). *p<0.05, **p<0.01, ***p<0.001 by unpaired Student t tests.
Figure 6. Modulation of AMPKα and ROS reduces cardiovascular lesions during LCWE-induced KD vasculitis. (A, B) Heart sections H&E staining (A) and heart vessel inflammation score (B) of WT mice injected with either PBS and treated with MN58b (n=5), injected with LCWE and treated with PBS (n=10) or injected with LCWE and treated with MN58b (n=10) at one week post- LCWE injection. (C, D) Representative pictures of the abdominal aorta (C), maximal aorta diameter and abdominal aorta area measurements (D) from the mouse groups in (A, B). (E, F) Representative pictures of FLICA staining (E) and quantification (F) in heart tissue sections of LCWE-injected WT mice and LCWE-injected WT mice treated with MN58b, one week post-LCWE injection (n=5/group). White arrows indicate FLICA positive cells. Scale bars: 100μm. (G, H) Representative DHE staining (G) and ROS quantification (H) in abdominal aorta tissue cross-sections LCWE-injected WT mice and LCWE-injected WT mice treated with MN58b one week after LCWE injection (n=8-10/group). *p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey’s post-test analysis (Fig. 6B and Fig.6D) and unpaired Student t tests for all other panels.
**Figure 7: Metformin reduces cardiovascular lesions in the LCWE-dependent murine model of KD vasculitis.**

(A) Heart sections H&E staining and heart vessel inflammation score of WT mice injected with either LCWE+PBS or LCWE + Metformin (Metformin 300mg/kg/d i.p. from day -2 to day 7), two weeks post-LCWE injection (n=10/group). (B) Representative pictures of the abdominal aorta, maximal aorta diameter and abdominal aorta area measurements from LCWE+PBS or LCWE + Metformin treated mice (n=10/group), 2 weeks after LCWE injection. (C) Representative pictures of FLICA staining and quantification in heart tissue sections of LCWE+PBS or LCWE + Metformin treated WT mice, one week post-LCWE injection (n=5/group). White arrows indicate FLICA positive cells. Scale bars: 100μm. (D) IL-1β levels in the serum of WT mice injected with either LCWE+PBS or LCWE + Metformin, at one week post- LCWE injection (n=8-9/group). (E, F) Western blot analysis (E) and quantification (F) of complex I (CI), CII, CIII, CIV and CV reflecting mitochondrial content, in whole lysates of heart tissues collected from LCWE+PBS and LCWE + Metformin, one week post-LCWE injection (n=4/group). (G) Representative DHE staining and ROS quantification in abdominal aorta tissues cross-sections collected from LCWE+PBS or LCWE + Metformin treated mice, one-week post-injection (n=7-9/group, scale: 100μm). (H, I) Representative western blot analysis images (H) and quantification (I) of autophagy and mitochondrial fission markers in heart tissue whole lysate of LCWE+PBS and LCWE + Metformin treated mice, one week post-LCWE injection (n=8-9/group). *p<0.05, **p<0.01, ***p<0.001 by Mann-Whitney U test (Fig. 7G, and pDRP1 Fig. 7I) and unpaired Student t test for all other panels.